San Jose, March 10, 2026
The U.S.-based multinational Solesis inaugurated its new manufacturing plant in Costa Rica on Tuesday, the first facility in the country specialized in the production of applied biomaterials solutions using textiles and polymers for customs components for medical device companies.
“The opening of this facility underscores our commitment to delivering consistent, high‑quality products for our customers”, said John Witkowski, President and CEO of Solesis. “This milestone marks an exciting new chapter for Solesis and strengthens our ability to advance applied biomaterial solutions that are transforming the future of medicine.”
The new Solesis plant in Costa Rica, located at the Greenpark Free Trade Zone in El Coyol, Alajuela, features cleanrooms and controlled environments designed to deliver high-quality healthcare solutions for customers in the medical devices industry. These implantable textile components are critical to final medical devices, playing a vital role in the health and recovery of patients worldwide. Furthermore, the facility bolsters Solesis’ global capabilities, supporting innovation within the rapidly evolving vascular and surgical markets.
Acting Minister of Foreign Trade Indiana Trejos stated: “Solesis marks a milestone by becoming the first biomaterials manufacturer in Costa Rica, a step that elevates the country’s technological contribution to global medical manufacturing. At the Ministry of Foreign Trade, we continue working to facilitate trade and to create the conditions that make our country competitive and attractive for high-quality investment.”
Construction of Solesis’ new plant was completed in 2025. During the same year, site qualification processes were carried out for ISO 13485:2016 certification, along with equipment transfer and installation, as well as the hiring and training of personnel. In parallel, the different phases of product validation were completed.
“The inauguration of this new plant strengthens Costa Rica’s medical devices ecosystem, where more than 100 companies already operate, including several of the world’s leading manufacturers and developers of medical technologies in areas such as endoscopy, cardiology, orthopedics, ophthalmology, and diagnostics. The incorporation of increasingly complex processes, such as biomaterials manufacturing, opens new opportunities to expand the country’s advanced manufacturing capabilities and further diversify its productive base in high value-added sectors. These developments reflect the sector’s evolution toward increasingly specialized activities and reinforce Costa Rica’s position as a platform for the development of knowledge- and technology-intensive industries,” said Laura López, CEO of the Trade and Investment Promotion Agency of Costa Rica (PROCOMER).
The Solesis family of companies includes Secant Group, Polyzen and Charter Medical, which partners with their customers to support the development next-generation technologies and therapies for patient care worldwide.
About Solesis
Solesis is a leader specializing in biomaterials for the life sciences industry. Operating through its subsidiaries Secant Group, Polyzen and Charter Medical, Solesis develops and manufactures critical components and technologies for the medical device and biopharmaceutical industries. Headquartered in Telford, Pennsylvania, Solesis employs more than 500 people across seven facilities located in Pennsylvania and North Carolina, USA and Alajuela, Costa Rica. For more information, visit www.solesis.com.
